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osting by EAbstract Prognostic markers as CD38 and ZAP-70 and speciﬁc chromosomal abnormalities as del
17p have now been developed to reﬁne the risk of progressive disease in chronic lymphocytic leu-
kemia (CLL). This study analyzed 40 recently diagnosed, untreated B-CLL patients for CD38 and
ZAP-70 expression by ﬂow cytometry and for del 17p by conventional cytogenetics (CCG) and by
ﬂuorescence in situ hybridization (FISH) technique to evaluate their effect on the clinical course of
CLL and as risk factors for disease progression in addition to their impact on response to treatment
and disease outcome. Twenty healthy age- and sex-matched subjects were included as a control. The
results revealed that CD38 and ZAP-70 expression were detected in 42.5% and 47.5% of cases,
respectively. They were associated with an unfavorable clinical course. Higher levels were signiﬁ-
cantly associated with increased risk of unfavorable response to treatment (P= 0.003), with poor
clinical outcome (P= 0.0001). Del 17p was detected in 35% of cases by FISH technique and in
7.5% by CCG. The deletion was signiﬁcantly associated with progressive clinical course; poor
response to treatment (P= 0.007) but not with disease outcome (P= 0.103).
Combined analysis of ZAP-70 and CD38 yielded concordantly negative results in 50% of patients
and concordantly positive results in 40% of patients, while 10% were discordant. CD38+/ZAP-70+0578877.
m (N.S. El-Kinawy).
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174 N.S. El-Kinawy et al.patients were signiﬁcantly associated with progressive disease (P< 0.05) and with del 17p than
CD38/ZAP-70- patients (P= 0.008).
Time to disease progression (TDP) was 6 months among CD38+/ZAP-70+ patients as compared
to 16 months in CD38/ZAP-70 patients. In patients with discordant results, the TDP was
9 months. Over-representation of the three parameters (CD38, ZAP-70 and del 17p) was detected
in 22.5% of cases, and pointed towards even shorter TDP (4.5 months), more aggressive disease;
more resistance to chemotherapy and poor outcome thus providing a precise tool for identifying
high-risk patients.
In conclusion, the combined expression of CD38 and ZAP-70 together with del 17p in CLL is a
precise diagnostic tool for identifying high-risk patients and convey rapid progression; they are
accurate predictors of clinical outcome thus could be used to indicate when more novel chemother-
apeutic approaches are needed and provided help in guiding individual patient treatment.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The clinical behavior of patients with chronic lymphocytic leu-
kemia (CLL) is heterogeneous. Some patients have indolent
disease without complications for many years others develop
progressive disease requiring therapy within a short time after
diagnosis. Early treatment of the former could lead to therapy-
related complications that might compromise their quality of
life and/or survival [1,2]. Deﬁning markers that reliably can
stratify patients into groups with good-risk or poor-risk dis-
ease could facilitate clinical trials evaluating the potential ben-
eﬁt of early treatment [3].
Gene expression analysis found that the expression of
unmutated immunoglobulin heavy chain variable region genes
(IGHV) predicts more aggressive CLL than the mutated
IGHV [4] as they express a relatively small subset of genes,
one of which encodes the zeta-chain associated protein of
70 kDa (ZAP-70). Measurements of this intracellular protein
can be used as a surrogate marker for expression of U-IGHV
[5].
ZAP-70 is a member of the syk family protein tyrosine ki-
nases (PTKs); which plays a critical role in T-cell antigen
receptor (TCR) signaling and T-cell development [6]; was
found to be associated with the B-cell receptor (BCR) in
CLL. CLL cells expressing high levels of ZAP-70 were found
to be associated with enhanced signal transduction via the
BCR complex, when compared to CLL cells with low expres-
sion of ZAP-70 [5].
CD38 ligation on mature B-cells protects it against apopto-
sis and upregulates the expression of Bcl-2 protooncogene [7].
It was observed that IgVH gene conﬁguration and high expres-
sion of CD38 were associated with poor prognosis in CLL.
Other abnormalities associated with poor prognosis include
deletions on chromosome 17p (p53 locus). This structural
abnormality reﬂects the loss of genetic information at speciﬁc
loci and consequently loss of its tumor suppression activity
which may be involved in the pathogenesis of these tumors
[8] and presumably account for much of the chemotherapy
resistance of this disease [2,9].
Thus the aim of this study is to evaluate patients with CLL
for CD38 and ZAP-70 expression by immunophenotyping; to
detect the existence of 17p deletion by conventional karyotyp-
ing and FISH technique; to detect their relation to clinical
progression; response to treatment and clinical outcome of
the disease and to correlate between their presence and bad
prognostic parameters.2. Subjects and methods
2.1. Study population
This study included 40 recently diagnosed, untreated B-CLL
patients who were presented to Hematology Oncology Clinic,
Ain Shams University Hospitals in the period from June 2008
to May 2010. They were 24 males and 16 females, with a male
to female ratio of 1.5:1. Their mean age was 58.7 ± 10.9 years.
Twenty healthy age- and sex-matched subjects were considered
as a control group.
Patients were selected and diagnosed as CLL according to
the International CLL Workshop Criteria and staged accord-
ing to Binet and Rai system [10]: Peripheral blood (PB) persis-
tent absolute lymphocytosis (>5 · 109/L) for at least 3 months
period and a characteristic immunophenotype: CD5+,
CD19+, CD23+, restricted K or k light chain expression
and CD5/CD19 co-expression. Patients showing negative
CD23 and CD5 expression were excluded.
During the follow-up period, patients were treated by one
of the following lines depending on age, performance status
and stage of the disease: Chlorambucil orally (0.2 mg/kg/
day) and prednisone (20 mg/m2/day); CVP regimen: Cyclo-
phosphamide (400 mg/m2/IV on days 1–3), Vincristine (1.4
mg/m2 IV on day 1) and oral prednisone (100 mg/m2 on days
1–5); Fludarabine (25 mg/m2 IV on days 1–3) and cyclophos-
phamide (250 mg/m2 IV on days 1–3).
Follow-up of patients to evaluate response to initial chemo-
therapy after 3–6 cycles. According to symptoms, organomeg-
aly, lymphadenopathy, hemoglobin (Hb) levels, platelet
counts, PB and bone marrow (BM) lymphocytes, patients were
classiﬁed into complete remission (CR), partial remission (PR),
progressive disease (PD), or stable disease (SD).
The patients were followed up over a period of 18–24
months to detect time to disease progression (TDP) (duration
from date of initial response until disease relapse or progres-
sion) and to evaluate the disease outcome.
2.2. Methods
2.2.1. Routine investigations
All patients and controls were subjected to the following:
– Thorough clinical history and examination particularly for
pallor, purpuric eruptions, hepatomegaly, splenomegaly
and lymphadenopathy.
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ical staging.
– Laboratory investigation, including liver and kidney func-
tion tests and serum lactic dehydrogenase (LDH). Complete
blood count (CBC), using Coulter (GenS) (Coulter elec-
tronics, Bechman, USA) with examination of Leishman-
stained peripheral blood (PB) smears
2.2.2. Bone marrow aspiration and biopsy
This was done for patients only for morphological examina-
tion and to detect the type of inﬁltration.
2.2.3. Immunophenotyping (IPT)
IPT of lymphocytes from lysed whole peripheral blood using
Coulter Epics XL Flow cytometer (Hialeah, FL, USA)
2.2.3.1. Conﬁrming the diagnosis of CLL using the following
monoclonals (Dako). Fluorescein isothiocyanate conjugated
CD45, CD3, CD4, CD20, FMC7, HLADR kappa light chains;
Phycoerythrine (PE) conjugated CD5, CD23, CD10, CD22,
CD56, CD79b, CD8, lambda light chain; Phycoerythrine-Cya-
nine 5 (PECya5) conjugated CD19.
2.2.3.2. Estimation of surface CD38 and cytoplasmic ZAP-70
expression [11] using monoclonal antibodies. PE conjugated
CD38 (Dako) and FITC conjugated ZAP-70 (Becton Dickin-
son, San Jose, CA, Bioscience) with an intrastain kit (Dako)
provided with a permeabilizing agent. Speciﬁc isotypic control
for FITC, PE and PC-5 (negative control) conjugated mono-
clonal antibody was used.
Lymphocytes were selected in the forward scatter versus
side scatter dot blot and additionally gated as CD19/CD5 po-
sitive cells. Results were expressed as a percentage of gated
cells showing positive expression over the corresponding iso-
typic control with cutoff >20% for ZAP-70 and >30% for
CD38 (Fig. 1).
2.2.4. Cytogenetic analysis of 17p (p53) deletion
2.2.4.1. Conventional cytogenetic analysis (CCA) (G-banding)
[8]. Principle: It depends on the examination of spontaneously
dividing cell population by blocking cell division at metaphase
stage with an inhibitor of spindle formation (Colcemid). The
procedure was done according to classic technique. Setup of
four cultures was done under complete aseptic conditions (di-
rect, short term, over night exposure to colcimide and 72 h cul-Figure 1 Flow cytometric representations of CD38 expressiotures) followed by harvesting, slide preparation, banding and
slide analysis on chromoscan image system. At least 230
banded metaphase spreads were counted and analyzed. Meta-
phase were karyotyped and interpreted according to the Inter-
national System for Human Cytogenetic Nomenclature
2.2.4.2. Fluorescence in situ hybridization (FISH) of 17p (p53)
deletion using labeled LSI probe [12] (Kreatech Biotechnology
Amsterdam, Netherlands). Principle: Target DNA was dena-
tured and hybridized to chemically modiﬁed single stranded
nucleic acid (ﬂuorophore-labeled) probe, homologous to tar-
geted genomic DNA sequence (17p13.1) using locus speciﬁc
identiﬁer (LSI) Tp53 probe (Vysis). Reaction conditions were
adjusted so that hybridization only occurs between probe
and target DNA sequence of high hemology followed by coun-
ter staining by a DNA speciﬁc ﬂorescent dye (DAPI) that
emits in different range.
Results were interpreted by scanning most viable meta-
phase and at least 100 interphase (for clear signals, no overlap-
ping or splitting) in every case under the chromoscan.
Hybridization of LSI Tp53 probe to normal cells revealed
two red signals, while abnormal cells revealed single red signal
(Fig. 2). A case was considered positive for 17p deletion if
>6% of nuclei showed single red signal.
2.3. Sampling
For CBC and IPT: 3 mL of peripheral blood (PB) was col-
lected on EDTA divided in two sterile vacutainers. Another
2 mL blood was collected and left to clot for LDH. For cyto-
genetic analysis and FISH: 1 mL PB collected in sterile vacu-
tainers coated with preservative free heparin. Adequate
amount of BM aspirate and biopsy was used for BM examina-
tion from patients only. The PB samples were processed within
6–24 h of collection, preserved at room temperature (22–
24 C).
2.4. Statistical analysis
Data was analyzed using SPSS statistical package version 12.
Numerical data were expressed as mean and standard error
of mean (SEM). Qualitative data was expressed as frequency
and percentage. Differences between groups were evaluated
using Student’s t -test for quantitative data and Chi-square
(v2) test for qualitative variables. P value less than 0.05 was
considered signiﬁcant.n and ZAP-70 expression on CD5+CD19+ B-CLL cases.
Figure 2 Interphase FISH analysis positive for p53 deletion (one
red signal represents one copy of chromosome 17).
176 N.S. El-Kinawy et al.3. Results
3.1. Basic characteristics of study population
The results of this study are illustrated in Tables 1–3, Figs. 1–5.
Clinically, among the 40 studied patients 28 (70%) patients
had lymphadenopathy, 24 (60%) had organomegaly.
Regarding patients’ clinical staging (Rai classiﬁcation), 3Table 1 Comparison between measured parameters in patients with
versus negative patients.
Parameters (n) CD38 ZAP-70
+(17)n (%) (23)n (%) v2 P +(19)n (%)
Sex
M(24) 7(41.2) 17(73.9) 3.1 0.07 10(52.6)
F(16) 10(52.8) 6(26.1) 9(47.4)
LN
+(28) 13(76.5) 15(65.9) 0.58 0.44 15(78.9)
(12) 4(23.5) 8 (34.8) 4(21.1)
OM
+(24) 13(76.5) 11(47.8) 3.34 0.06 13(68.4)
(16) 4(23.5) 12(52.2) 6(31.6)
Rai staging
0(3) – 3(13) –
1(4) – 4(17.4) 1(5.3)
2(10) – 10(43.5) –
3(8) 6(35.3) 2(8.7) 21.8 0.0001* 5(26.3)
4(15) 11(64.7) 4(17.4) 13(68.4)
BMinﬂ
D(17) 12(70.6) 5(21.7) 7.65 0.002* 13(68.4)
N(23) 5(29.4) 18(83) 6(31.6)
LDT (m)
<12(23) 17(100) 6(26.1) 21.8 0.0001* 18(94.7)
>12(17) – 17(73.9) 1(5.3)
Resp. to tt
Favorable(18) 1(5.9) 17(73.9) 18.2 0.0001* 1(5.3)
Unfavorable(22) 16(94.1) 6(26.1) 18(94.7)
Outcome
Good(17) – 17(73.9) 21.1 0.0001* 1(5.3)
Poor(23) 17 6(26.1) 18(94.7)
M: male; F: female; LN: lymphadenopathy; OM: organomegaly; BMinﬂ:
doubling time; m: months; Resp. to tt: response to treatment.
* Signiﬁcance level <0.05.(7.5%) were stage 0, 4 (10%) were stage I, 10 (25%) were
stage II, 8 (20%) were stage III and 15 (37.5%) were stage
IV (Table 1).
After initial chemotherapy, 18 (45%) patients showed
favorable response (CR or SD) while 22 (55%) showed unfa-
vorable (PR or PD). During the follow-up period, patients
were classiﬁed according to disease outcome into good 17
(42.5%) versus poor outcome 23 (57.5%). Six patients died
(15%) due to causes related to CLL.
3.2. Immunophenotypic analysis
All cases were positive for CD5, CD19, CD23 expression,
as well as CD5/CD19 co-expression, and showed dim surface
Ig expression. Out of them 12 (30%) were positive for
FMC7 expression, 17 (42.5%) for CD38, 19 (47.5%) for
ZAP-70.
3.3. Cytogenetic analysis
3.3.1. Conventional cytogenetic analysis
Successful cultures with well spread metaphases were encoun-
tered in 31 (77.5%) of patients, 11/31 (35.5%) patients showed
normal karyotypes. While 20/31 (64.5%) patients showedpositive CD38, ZAP-70 expression and presence of p53 deletion
Del 17p
(21)n (%) v2 P +(14)n (%) (26)n (%) v2 P
14(66.7) 0.81 0.28 8(57.1) 16(61.5) 0.73 0.52
7(33.3) 6(42.9) 10(38.5)
13(61.9) 1.38 0.21 10(71.4) 18(69.2) 0.02 0.59
8(38.9) 4(38.6) 8(30.8)
11(52.4) 1.06 0.31 8(57.1) 16(61.5) 0.07 0.52
10(47.6) 6(42.9) 10(37.5)
3(14.3) 1(7.1) 2(7.7)
3(14.3) 1(7.1) 3(11.5)
10(47.6) – 10(38.5)
3(14.3) 22.5 0.0001* 4(28.6) 4(15.4) 8.57 0.07
2(9.5) 8(57.1) 7(26.9)
4(19) 9.92 0.002* 10(71.4) 7(26.9) 7.37 0.007*
17(81) 4(28.6) 19(73.1)
5(23.8) 17.7 0.0001* 12(85.7) 11(48.3) 5.35 0.02*
16(76.2) 2(14.3) 15(57.7)
17(81) 20.1 0.0001* 4(28.6) 14(53.8) 5.35 0.01*
4(19) 10(71.4) 12(46.2)
16(76.2) 20.5 0.0001* 2(14.3) 15(57.7) 2.65 0.103
5(21.7) 12(85.7) 11(42.3)
bone marrow inﬁltration; D: diffuse; N: nodular; LDT: lymphocyte
Table 3 Correlation between combined expression of CD38 and ZAP and some studied parameters.
Parameters(n) CD38 + ZAP (1) CD38  ZAP+ (3) CD38 + ZAP+ (16) CD38  ZAP (20) v2 P
Sex
M(24) – 2(66.7) 8(50) 14(70) 30.5 0.33
F(16) 1(100) 1(33.3) 8(50) 6(30)
LN
+(28) – 2(66.7) 13(81.2) 13(65)
(12) 1(100) 1(33.3) 3(18.8) 7(35) 3.55 0.29
OM
+(24) 1(100) 2(66.7) 11(68.8) 10(50)
(16) – 1(33.3) 5(31.3) 10(50) 2.42 0.49
Rai staging
0(3) – – – 3(15)
1(4) – 1(33.3) – 3(15)
2(10) – – – 10(50) 31.9 0.001*
3(8) 1(100) – 5(31.2) 2(10)
4(15) – 2(66.7) 11(68.8) 2(10)
BMinﬂ
D(17) – 1(33.3) 12(75) 4(20)
N(23) 1(100) 2(66.7) 4(25) 16(80) 11.9 0.008*
LDT
<12(23) 1(100) 2(66.7) 16(100) 4(20)
>12(17) – 1(33.3) – 16(80) 24.2 0.0001*
Del 17p
+(13) 1(100) 2(66.7) 9(56.2) 1(10)
(27) – 1(33.3) 7(43.8) 19(90) 11.8 0.008*
Resp. to tt
Response(18) 1(100) 1(33.3) – 16(80) 24.3 0.0001*
No resp.(22) – 2(66.7) 16(100) 4(20)
Outcome
Good(17) – 1(33.3) – 16(80) 24.1 0.0001*
Poor(23) 1(100) 2(66.7) 16(100) 4(20)
M: male; F: female; LN: lymphadenopathy; OM: organomegaly, BMinﬂ: bone marrow inﬁltration, LDT: lymphocyte doubling time; Resp. to
tt: response to treatment.
* Signiﬁcance level <0.05.
Table 2 Correlation between CD38, ZAP70 and del 17p expression and prognostic factors.
Parameters CD38 ZAP-70 Del 17p
r P r P r P
Age (years) 0.71 0.66 0.265 0.09 0.37 0.01*
TLC (·109/L) 0.45 0.785 0.39 0.01* 0.05 0.75
Hb (g/dL) 0.386 0.01* -0.62 0.0001* 0.39 0.01*
Plat (·109/L) 0.34 0.02* 0.53 0.0001* 0.21 0.18
AbsLym (·109/L) 0.07 0.66 0.47 0.02* 0.104 0.52
BMLym (%) 0.21 0.20 0.58 0.0001* 0.22 0.16
LDT (m) 0.58 0.0001* 0.78 0.0001* 0.41 0.007*
LDH (mg/dL) 0.62 0.0001* 0.77 0.0001* 0.62 0.0001*
ZAP-70 (%) 0.77 0.0001* – – 0.54 0.0001*
Del 17p 0.431 0.005* 0.547 0.0001* –
Hb: hemoglobin; Plat: platelets; TLC: total leukocytic count; Abs. lymph: absolute lymphocyte count; BMlym: bone marrow lymphocytes;
LDT: lymphocyte doubling time; LDH: lactic dehydrogenase.
* Signiﬁcance level <0.05.
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the form of trisomy 12 in 6/31 (19.3%) patients or structural
abnormalities as follows: del 13q14 in 5/31 (16.1%) patients,del 17p13 in 3/31 (9.6%), del 6q in 2/31 (6.5%) patients. 2/
31 (6.5%) patients with 11q rearrangement and 2/31 (6.5%)
had 14q rearrangement.
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Figure 3 Kaplan–Meier curve TDP for CD38, ZAP-70 and Del 17p expression.
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Figure 4 Kaplan–Meier curve TDP for combined CD38/ZAP-70
expression.
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All the 40 patients were re-evaluated using metaphase and
interphase FISH analysis, 14 (35%) patients were positive
for deletion of 17p.
3.3.3. Comparative and survival study
According to CD38, ZAP expression and presence of del 17p,
patients were stratiﬁed into positive or negative expressor.
High CD38 expression was associated with advanced Rai
staging, diffuse bone marrow inﬁltration and low lymphocyte
doubling time (LDT) (P< 0.05; Table 1). CD38 levels were
correlated negatively to Hb levels, platelet counts, LDT and
positively to BM lymphocytes and LDH (P< 0.05; Table 2).
ZAP-70 expression was signiﬁcantly associated with ad-
vanced Rai stages as 94.7% of patients expressing ZAP-70 were
in stages 3 and 4 (P= 0.0001). Positive expression was signiﬁ-
cantly associated with diffuse pattern of bone marrow inﬁltra-
tion (P= 0.007) and with LDT <12 months (P= 0.0001;
Table 1). ZAP-70 levels were signiﬁcantly positively correlated
to TLC, absolute lymphocytes in PB, BM lymphocytes and
LDH values, while it was negatively correlated to Hb levels,
platelet counts and LDT (P< 0.05; Table 2).
Regarding response to treatment and outcome, CD38 and
ZAP-70 expression were signiﬁcantly associated with non-
responsiveness to initial chemotherapy and poor outcome
(P= 0.000; Table 1).
CD38 and ZAP-70 levels were correlated to each other with
a high statistical signiﬁcant difference (P= 0.0001; Table 2).
Patients harboring 17p deletion had statistically signiﬁcant
association, as regards the pattern of BM inﬁltration
(P= 0.007), LDT (P= 0.02), but not with the Rai staging
(P= 0.07). 71.4% of patients with 17p deletion showed unfa-
vorable response to initial chemotherapy which is statistically
higher than those not harboring the deletion (P= 0.0001).
However, the presence of 17p13 deletion was not statistically
associated with disease outcome (P= 0.103; Table 1). Corre-
lation with bad prognostic criteria of CLL showed a signiﬁcant
negative correlation between del 17p and age, Hb, LDT and a
signiﬁcant positive correlation with LDH levels (P= 0.000).
Again, a positive signiﬁcant correlation was detected between
del 17p13 and both CD38 and ZAP-70 (P= 0.005 and
0.000, respectively; Table 2).
Combined analysis of ZAP-70 and CD38 yielded that 40%
of patients were CD38+/ZAP-70+ and 50% were CD38/ZAP-70; P < 0.001), while the remaining 10% were discor-
dant (CD38+/ZAP-70 or CD38/ZAP-70+) (Table 4).
CD38+/ZAP-70+ patients were characterized by being associ-
ated with advanced Rai stages, diffuse type of BM inﬁltration,
shorter lymphocyte doubling time (LDT); and show more fre-
quent abnormalities in chromosome 17 than the other subsets
of patients with a high statistical signiﬁcant difference
(P< 0.05). While CD38/ZAP-70 were signiﬁcantly associ-
ated with earlier Rai stages, nodular BM inﬁltration, longer
LDT (>12 m), good response to treatment and better outcome
(P< 0.05), while the discordant groups (CD38+/ZAP-70
and CD38/ZAP-70+) showed variable associations (Table
4). Thus, ZAP-70 and CD38 expression analyses provided
information identifying three patient subgroups with good,
intermediate and poor prognosis.
The time to disease progression (TDP) of CLL patients was
assessed by Kaplan–Meier curves and the Log-Rank test
(Fig. 3). Patients with CLL cells that were CD38 had longer
TDP (16.1 months, 95% CI 14.2–17.9), whereas those with
CD38+ CLL cells had shorter TDP (6.6 months, 95% CI
5.4–7.8) (Log-Rank test = 31.3; P= 0.0001). Again, patients
with ZAP-70 CLL cells had a TDP of 16.5 months 95% CI
(14.8–18.1), whereas those with ZAP-70+ cells had a TDP of
6.9 months and 95% CI (5.5–9.1) with a Log-Rank test of
TPS: Prognostic Signiﬁcance of del 17p, ZAP-70 and CD38 in B-CLL 17933.1 and a high statistical signiﬁcance (P= 0.0001). While del
17p carriers showed a TDP of 8.2 months with a 95% conﬁ-
dence interval of (4.8–11.7) while non-carriers showed a TDP
of 13.7 month (CI: 11.7–15.8) with a non-signiﬁcant Log-Rank
test (P< 0.05).
CLL patients with CD38+/ZAP-70+ had a mean survival
time of 6.1 months with a 95% CI of (5.01–7.36), whereas
those with CD38-/ZAP-70 had a TDP of 16.3 months a
95% CI (14.7–17.8). On the other hand, patients with discor-
dant results had a TDP of 9 months with a 95% CI (6.01–
11.9) (Fig. 4).
Combined analysis of CD38, ZAP-70 and del 17p13 yielded
that the three parameters were positive in nine patients
(22.5%), 10 patients (25%) were positive for two parameters,
three patients (7.5%) were positive for one parameter only,
whereas 18 patients (45%) were negative for all parameters
and were shown to run a more benign course (Table 4).
Patients with CLL cells positive for one parameter had a
TDP of 12 months with a 95% CI (4.2–19.8), whereas those
with two positive parameters had a TDP of 8.2 months with
a 95% CI (7.0–9.5). On the other hand, patients who had
CLL cells expressing the three parameters had a TDP of
4.5 months with a 95% CI (3.8–5.2), whereas those with nega-
tive CD38, ZAP-70 del 17p had a TDP of 16.7 months with a
95% CI (15.3–18.1) (Fig. 5).Table 4 Correlation between combined expression of CD38, ZAP-
Parameters (n) All positive (9) 2 positive (10) 1
Sex
M(24) 4(44.4) 6(60) 2
F(16) 5(55.6) 4(40) 1
LN
+(28) 7(77.8) 8(80) 1
(12) 2(22.2) 2(20) 2
OM
+(24) 5(55.6) 8(80) 2
(16) 4(44.4) 2(20)) 1
Rai staging
0(3) – – 1
1(4) – 1(10) –
2(10) – – –
3(8) 3(33.3) 3(30) –
4(15) 6(66.7) 6(60) 2
BMinﬂ
D(17) 8(88.9) 5(50) 1
N(23) 1(11.1) 5(50) 2
LDT
<12(23) 9(100) 9(90) 2
>12(17) – 1(10) 1
Resp. to tt
Response(18) – 2(20) 2
No resp.(22) 9(100) 8(80) 1
Outcome
Good(18) – 2(20) 2
Poor(22) 9(100) 8(80) 1
M: male; F: female; LN: lymphadenopathy; OM: organomegaly, BMinﬂ:
tt: response to treatment.
* Signiﬁcance level <0.05.4. Discussion
The current challenge is the identiﬁcation of CLL patients at
high risk, at time of diagnosis, for therapy-tailoring [13].
Molecular-targeted therapy, aiming to elucidate the existing
genetic aberration, was found to play a crucial role in the
improvement of patient response [14]. In recent years it has be-
come evident that CLL patients with unmutated IgVH gener-
ally have more aggressive disease and shorter overall survival
[1]. CD38, a marker associated with CLL, was found to corre-
late with IgHV mutational status [7]. Recently, ZAP-70 was
shown to be highly expressed in CLL patients with unmutated
status and to be correlated with disease progression, and over-
all survival [4]. Thus assays for CD38 and ZAP-70 expression
would yield important prognostic information for patients
with CLL [5].
In the current study, 42.5% of patients showed high levels
of CD38. Similar results were reported recently [15] suggesting
that high expression of CD38 simply reﬂects an increased cel-
lular turnover due to loss of CD38 when CLL cells enter the
circulation. While other reports showed low percentage of
CD38 positivity [2,7]. This discrepancy may be attributed to
the fact that CD38 expression can change with time and after
receiving chemotherapy which selectively eliminate the CD38
clone. Thus it was proposed that, for accurate assessment of70 and del 17p and some studied parameters.
positive (3) All negative (18) v2 P
(66.7) 12(66.7) 1.29 0.37
(33.3) 6(33.3)
(33.3) 12(66.7) 2.75 0.45
(66.7) 6(33.3)
(66.7) 9(50) 2.54 0.45
(33.3) 9(50)
(33.3) 2(11.1)
3(16.7)
10(55.6) 30.2 0.006*
2(11.1)
(66.7) 1(5.6)
(33.3) 3(16.7) 13.1 0.004*
(66.7) 15(83.3)
(66.7) 3(16.7) 23.3 0.001*
(33.3) 15(83.3)
(66.7) 14(77.8) 20.6 0.0001*
(33.3) 4(22.2)
(66.7) 14(77.8) 20.8 0.0001*
(33.3) 4(22.8)
bone marrow inﬁltration, LDT: lymphocyte doubling time; Resp. to
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Figure 5 Kaplan–Meier curve TDP for combined CD38, ZAP-
70, del 17p expression.
180 N.S. El-Kinawy et al.its prognostic signiﬁcance, only samples close to or at the time
of presentation was tested. Again in this study, a signiﬁcant
correlation was found between CD38 levels and some of B-
CLL poor prognostic parameters. In accordance to earlier re-
ports [3,16] suggesting that CD38 measurement is a powerful
prognostic tool that should be considered as a standard clinical
test for B-CLL patients.
Furthermore, in this study 47.5% of the patients were ZAP-
70 positive as previous reports [5,6]. Analysis of the clinical
characteristics of our CLL patients revealed that those who
had clinical progress (more advanced clinical stage, diffuse
type of BM inﬁltration or a LDT<12 months) also had higher
ZAP-70 levels compared to patients with stable disease and
that its levels were signiﬁcantly correlated to some of B-CLL
poor prognostic parameters. This is in accordance with earlier
studies reporting that ZAP-70 expression is correlated to dis-
ease progression and aggressiveness [17]. Conceivably, some
studies have not found ZAP-70 to be an independent risk fac-
tor for aggressive disease [18]. This might be related to the
methods used for determining the expression of this intracellu-
lar tyrosine kinase, thus standardization using optimized ﬂow
cytometry methods can yield reproducible and consistent re-
sults as ZAP-70 was found to be a stable disease marker [19].
The present work showed the superiority of FISH over CCA
in detection of minute genetic aberrations and its capability of
analyzing interphase as well as metaphase, besides the CLL cells
often exhibit low yields of viable metaphase despite the use of B-
cell mitogens consequently 14 (35%) cases were positive for del
17p by FISH using LSI, compared to only 3 (7.5%) of all cases
detected by CCA. The ability of detection of the deletion by
CCA might be hampered by failure of mitosis, fuzzy chromo-
somal morphology, poor quality of metaphase spread, poor
staining chromosomal pattern, in addition to low index and
low density [8]. Again, previous works showed variable results
of detected 17p deletion by FISH [14,20–22]. This discrepancy
could be attributed to different methods of detection, sample
size and/or various studied ethnic groups.
In this study, diffuse BM inﬁltration and shorter LDT were
found to be signiﬁcantly associated with the presence of del 17p.
Again the deletion was correlated negatively with hemoglobin
and positively with LDH. This deletion appear to contribute
to disease progression with survival of less than 2 years [20,22].
Regarding response to treatment, this study showed that
high levels of CD38 or ZAP-70 were signiﬁcantly associatedwith non-responsiveness to initial chemotherapy indicating
that these biological factors might be used to predict the che-
mo-sensitivity of B-CLL patients as previous studies [1,17].
Other investigators added that the overall response rate and re-
sponse duration could be worse in those patients [23].
Again, our patients with del 17p were signiﬁcantly more
resistant to therapy than non-deleted cases. Similarly previous
studies [13,24] showed that abnormalities of 17p convey resis-
tance and alter the sensitivity of CLL cells to chemotherapeu-
tic agents with lower response rate and early relapse after
autologous stem cell transplantation. Others showed evidences
on the efﬁciency of anti-monoclonal antibody therapy in CLL
with 17p gene abnormality [1].
In the present study, disease outcome was statistically asso-
ciated with high expression of CD38 or ZAP-70 on the lym-
phocytes as previously reported [23]. The expression of these
markers was associated with adverse outcome in CLL and
was considered as an important risk factors in these patients.
However, despite having 17p13 deletion, no statistically signif-
icant association was detected with disease outcome in our pa-
tients. This was also previously documented [21]. On the
contrary, the association between 17p13 deletion and poor
outcome has been previously reported [8,13,14,22].
CD38 is a cell-surface receptor mediating interactions
which sustain proliferation and survival [9]. Co-expression of
CD38 and ZAP-70 in CLL was suggested to form part of
the same signaling pathway or that they intersect in some
steps. CD38 ligation directly triggers the cytoplasmic tyrosine
kinase ZAP-70 phosphorylation [23]. It was proved that CD38
pathway is selectively active in CD38+/ZAP-70+ cells, while
CD38+/ZAP-70 patients were consistently unable to signal
via CD38 [25].
The existence of a functional link between the two mole-
cules in neoplastic B-cells prompted us to evaluate the effects
of their coexpression. In this study, combined analysis of
ZAP-70 and CD38 yielded discordant results in 10% of pa-
tients, whereas 50% of the patients were concordantly negative
and 40% of them were concordantly positive for ZAP-70 and
CD38 expression in accordance to a previous study [19]. Clin-
ically, advanced Rai stages, diffuse BM inﬁltration together
with LDT less than 12 months were mostly associated with
CD38+/ZAP-70+ group followed by the discordant group
and were least with CD38/ZAP-70 group. Thus ZAP-70
and CD38 expression provided complementary prognostic
information identifying three patient subgroups with good,
intermediate and poor prognosis. Similar results were obtained
in a previous report suggesting that concordantly positive
group was associated with an active and aggressive disease
with greatest proliferative potential [3] thus it was proposed
that simultaneous testing of CD38 and ZAP-70 provides a tool
for risk stratiﬁcation of patients [1].
In this study, CD38+/ZAP-70+ group was found to be
more signiﬁcantly resistant to chemotherapy as previously
reported [1,3] that these patients required treatment with
polychemotherapy or combined immunochemotherapy com-
pared with CD38ZAP-70 patients who were either un-
treated or treated with chorambucil monotherapy.
Our CD38+/ZAP-70+ patients had a mean time to disease
progression of 6.1 months, whereas those with CD38/ZAP-
70 had a TDP of 16.3 months, on the other hand patients
who where discordant, had a TDP of 9 months as previously
reported [16].
TPS: Prognostic Signiﬁcance of del 17p, ZAP-70 and CD38 in B-CLL 181In this study, there was a signiﬁcant association between
CD38%, ZAP-70 expression and presence of del 17p. The three
parameters were detected on the lymphocytes of 22.5% of
patients and were all absent in 45% of patients. While, two
of them were present in 25% and only one parameter was
positive in 7.5% in accordance to previous reported data [23].
Again, CD38+/ZAP-70+ patients who harbored del(17p)
were signiﬁcantly associated with advanced stages of Rai stag-
ing, diffuse type of BM inﬁltration, lower LDT, and were more
resistant to treatment than those expressing low levels, in excel-
lent agreement with the published literature [24]. It was also
shown that cases with high CD38, ZAP-70 and harboring
del(17p) had signiﬁcantly increased resistance to chlorambucil
and ﬂudarabine [1].
Kaplan–Meier analysis of the patients showed signiﬁcantly
lower TDP (4.5 months) in patients with higher ZAP-70, CD38
expression and carrying del 17p, while those with negative
CD38, ZAP-70 and del 17p had a TDP of 16.7 months,
whereas TDP was 8.2 months in patients with two parameters
positive, and was 12 months in patients with cells positive for
one parameter only. Similar results were previously shown
by other investigators [23] who added that over representation
of the high-risk genomic aberration 17p deletion in B-CLL dis-
cordant for CD38/ZAP-70 pointed towards a distinct biologic
background of the observed disease subgroups. This ﬁnding
was also supported by gene expression proﬁling where the
expression of 37 genes differed signiﬁcantly between the groups
deﬁned by their expression of ZAP-70 and CD38, including
genes that are involved in regulation of cell survival and che-
motherapy resistance [13].
In conclusion, the combined expression of CD38 and ZAP-
70 together with del 17p in CLL is a precise diagnostic tool for
identifying high-risk patients and convey rapid progression;
they are accurate predictors of clinical outcome thus could
be used to indicate when more novel chemotherapeutic ap-
proaches are needed and provided help in guiding individual
patient treatment.
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